ReviewiScience2026
ADAM and ADAMTS proteases as integrative hubs in heart failure pathogenesis and therapy.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) arises from multifactorial disruptions in cellular signaling, inflammation, and tissue remodeling beyond classical neurohormonal regulation. Increasing evidence highlights ADAM and ADAMTS metalloproteinases as central integrators of inflammatory, fibrotic, and hypertrophic pathways. This review establishes a dual integrative framework. Horizontally, distinct protease family members converge within each pathological axis, including inflammation, fibrosis, hypertrophy and remodeling, metabolism, and angiogenesis, to drive disease progression. Vertically, individual proteases, such as ADAM17, coordinate multiple axes through various effectors that activate distinct downstream pathways, exhibiting both detrimental and protective functions. These mechanistic insights guide the development of selective inhibitors to circumvent pitfalls associated with broad-spectrum MMP targeting. Additionally, emerging ADAM and ADAMTS family members show promise as diagnostic and prognostic biomarkers in cardiovascular diseases (CVDs). By synthesizing mechanistic depth with translational relevance, this framework reveals protease-centered opportunities for precision intervention and outlines essential future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.